BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Watson Pharmaceuticals, Inc. (WPI) Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines


8/6/2012 10:18:43 AM

PARSIPPANY, N.J., Aug. 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today applauded the publication of the fourth annual Generic Pharmaceutical Association (GPhA) Generic Drug Savings Study demonstrating that the generic pharmaceutical industry has saved the U.S. healthcare system more than $1 trillion in the last decade. The study is available on the GPhA website: www.gphaonline.org.

The study, based on an independent analysis of data by IMS Health the world's leading provider of market intelligence to the pharmaceutical and health care industries found that in 2011 alone, the use of generic drugs generated nearly $193 billion in savings, an average of $1 billion every other day. The study also highlighted that 17 of the 22 first-time generics launched in 2011 were the result of patent settlements that have enabled dozens of first-time generics to come to market many months and even years before patents on the counterpart brand drugs expired.

"As the third largest generic pharmaceutical company in the United States, Watson is proud of its contribution to this extraordinary record of savings," said Paul Bisaro, President and CEO and past Chairman of the Board of GPhA (2010-2011). "Generic drugs are an integral part of the solution in reigning in U.S. health care costs. Through the hard work of Watson's scientists, manufacturing, quality and other employees in every division across our company, and those of our colleagues in the U.S. generic industry, consumers save when they use FDA-approved, safe and effective generic prescription drugs at prices they can afford."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:


Lisa DeFrancesco


(862) 261-7152




Media:


Charlie Mayr


(862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES